Ranexa Approval History
- FDA approved: Yes (First approved January 27th, 2006)
- Brand name: Ranexa
- Generic name: ranolazine
- Company: CV Therapeutics, Inc.
- Treatment for: Angina
Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.
FDA Approval History for Ranexa
|Nov 6, 2008||FDA Approves Ranexa for First Line Anti Anginal Use|
|Dec 19, 2007||FDA Approves New Mechanism of Action Labeling for Ranexa|
|Aug 14, 2007||CV Therapeutics Launches 1000 mg Ranexa Tablet|
|Jan 27, 2006||Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina|
|Jul 27, 2005||CV Therapeutics Submits Amendment to Ranexa (ranolazine)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.